2026-10-13T12:43:40Z https://api.figshare.com/v2/oai

oai:figshare.com:article/34031605 2026-09-30T11:15:23Z category_7 category_21 category_272 category_45 category_734 category_106 category_132 portal_87 item_type_3 month_year_09_2026

Defining value criteria for outcomes-based managed entry agreements in CAR-T therapy for relapsed/refractory multiple myeloma: a multi-criteria decision analysis study María Victoria Mateos Manteca (25143460) José Luis Poveda Andrés (25143463) Albert Oriol Rocafiguera (25143466) Vicente Escudero-Vilaplana (9278957) José Luis Trillo Mata (25143469) Pedro Gómez Pajuelo (25143472) Alberto Arribas Ruiz (25143475) Teresa Domínguez Lubillo (25143478) Neus Vidal-Vilar (25143481) Asís Ariznavarreta Martín (25143484) Medicine Biotechnology Environmental Sciences not elsewhere classified Sociology Biological Sciences not elsewhere classified Science Policy Infectious Diseases CAR-T therapy EVIDEM framework health technology assessment managed entry agreements multi-criteria decision analysis outcomes-based agreements relapsed/refractory multiple myeloma <p>This study aimed to identify and prioritize criteria for designing and monitoring outcomes-based managed entry agreements (MEAs) for chimeric antigen receptor T-cell (CAR-T) therapy in relapsed/refractory multiple myeloma (RRMM), from the perspective of healthcare professionals and decision-makers.</p> <p>A structured MCDA-informed expert weighting exercise was conducted using an adapted EVIDEM framework. The study comprised two phases: a) selection and structuring of criteria through a targeted literature review and scientific committee (SC) consensus; and b) nonhierarchical weighting of criteria and sub-criteria by a multidisciplinary expert group (n = 19) of hospital pharmacists, physicians, and evaluators/decision-makers;</p> <p>Twelve criteria were identified. Following SC discussion, five criteria were selected for weighting: efficacy, safety, patient-reported outcomes, treatment cost, and other direct medical costs. Among the weighted sub-criteria, overall survival (OS) and progression-free survival (PFS) achieved the highest scores, with mean values of 4.21 (95% CI: 3.68–4.74) and 4.05 (95% CI: 3.52–4.58), respectively.</p> <p>In this structured MCDA-informed expert weighting exercise, OS and PFS were identified as the highest-priority value criteria for designing and monitoring outcomes-based MEAs for CAR-T therapies in RRMM. These findings may support feasible, evidence-based reimbursement models but require validation in larger and more diverse stakeholder groups.</p> 2026-09-30T11:15:23Z Dataset Dataset 10.6084/m9.figshare.34031605.v1 https://figshare.com/articles/dataset/Defining_value_criteria_for_outcomes-based_managed_entry_agreements_in_CAR-T_therapy_for_relapsed_refractory_multiple_myeloma_a_multi-criteria_decision_analysis_study/34031605 CC BY 4.0